Senti Biosciences (SNTI) Competitors $1.35 -0.03 (-2.17%) Closing price 04:00 PM EasternExtended Trading$1.35 0.00 (0.00%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNTI vs. CLLS, FBRX, IKT, CHRS, ACOG, CRDF, ZURA, CABA, HURA, and PLXShould you be buying Senti Biosciences stock or one of its competitors? The main competitors of Senti Biosciences include Cellectis (CLLS), Forte Biosciences (FBRX), Inhibikase Therapeutics (IKT), Coherus Oncology (CHRS), Alpha Cognition (ACOG), Cardiff Oncology (CRDF), Zura Bio (ZURA), Cabaletta Bio (CABA), TuHURA Biosciences (HURA), and Protalix BioTherapeutics (PLX). These companies are all part of the "pharmaceutical products" industry. Senti Biosciences vs. Its Competitors Cellectis Forte Biosciences Inhibikase Therapeutics Coherus Oncology Alpha Cognition Cardiff Oncology Zura Bio Cabaletta Bio TuHURA Biosciences Protalix BioTherapeutics Senti Biosciences (NASDAQ:SNTI) and Cellectis (NASDAQ:CLLS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership. Is SNTI or CLLS more profitable? Senti Biosciences has a net margin of 0.00% compared to Cellectis' net margin of -100.69%. Cellectis' return on equity of -68.05% beat Senti Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Senti BiosciencesN/A -223.98% -76.02% Cellectis -100.69%-68.05%-21.53% Does the media prefer SNTI or CLLS? In the previous week, Cellectis had 1 more articles in the media than Senti Biosciences. MarketBeat recorded 3 mentions for Cellectis and 2 mentions for Senti Biosciences. Cellectis' average media sentiment score of 1.61 beat Senti Biosciences' score of 1.45 indicating that Cellectis is being referred to more favorably in the news media. Company Overall Sentiment Senti Biosciences Positive Cellectis Very Positive Which has more risk & volatility, SNTI or CLLS? Senti Biosciences has a beta of 2.06, indicating that its share price is 106% more volatile than the S&P 500. Comparatively, Cellectis has a beta of 3.03, indicating that its share price is 203% more volatile than the S&P 500. Which has better valuation & earnings, SNTI or CLLS? Cellectis has higher revenue and earnings than Senti Biosciences. Cellectis is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSenti Biosciences$2.56M13.80-$52.79M-$8.95-0.15Cellectis$56.30M2.85-$36.76M-$0.82-3.52 Do insiders and institutionals have more ownership in SNTI or CLLS? 25.7% of Senti Biosciences shares are held by institutional investors. Comparatively, 63.9% of Cellectis shares are held by institutional investors. 3.1% of Senti Biosciences shares are held by company insiders. Comparatively, 16.4% of Cellectis shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Do analysts recommend SNTI or CLLS? Senti Biosciences currently has a consensus target price of $8.50, indicating a potential upside of 529.63%. Cellectis has a consensus target price of $4.00, indicating a potential upside of 38.41%. Given Senti Biosciences' higher possible upside, equities analysts clearly believe Senti Biosciences is more favorable than Cellectis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Senti Biosciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Cellectis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryCellectis beats Senti Biosciences on 10 of the 15 factors compared between the two stocks. Get Senti Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SNTI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNTI vs. The Competition Export to ExcelMetricSenti BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$35.32M$3.12B$5.79B$10.15BDividend YieldN/A2.32%5.69%4.61%P/E Ratio-0.1521.3074.5925.92Price / Sales13.80240.30449.5483.33Price / CashN/A45.3337.0859.91Price / Book0.259.6112.156.29Net Income-$52.79M-$53.29M$3.28B$270.85M7 Day Performance-2.88%0.29%0.98%3.36%1 Month Performance-8.78%8.91%7.20%6.41%1 Year Performance-56.45%13.14%63.06%28.26% Senti Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNTISenti Biosciences3.2328 of 5 stars$1.35-2.2%$8.50+529.6%-54.6%$35.32M$2.56M-0.154Short Interest ↓CLLSCellectis3.3777 of 5 stars$2.55-0.8%$4.00+56.9%+31.3%$141.79M$49.22M-3.11290Positive NewsShort Interest ↓Gap UpFBRXForte Biosciences3.3694 of 5 stars$11.11+1.0%$68.00+512.3%+47.5%$138.02MN/A-0.685News CoveragePositive NewsShort Interest ↓IKTInhibikase Therapeutics1.4658 of 5 stars$1.82+1.1%$6.50+257.1%+27.3%$135.62MN/A-0.686Positive NewsCHRSCoherus Oncology4.1648 of 5 stars$1.16+0.3%$4.68+302.3%+0.0%$134.25M$266.96M0.75330ACOGAlpha Cognition2.7141 of 5 stars$8.27-0.4%$20.00+141.8%N/A$133.64MN/A-5.17N/APositive NewsCRDFCardiff Oncology2.7073 of 5 stars$1.97-6.4%$10.10+414.0%-10.0%$132.73M$680K-2.2920News CoveragePositive NewsZURAZura Bio3.6701 of 5 stars$2.04-0.2%$14.00+588.0%-42.3%$132.32MN/A-2.913Positive NewsShort Interest ↓CABACabaletta Bio2.9915 of 5 stars$1.45-0.3%$14.43+898.5%-57.5%$132.16MN/A-0.5350News CoveragePositive NewsHURATuHURA Biosciences1.8853 of 5 stars$2.62-3.0%$12.67+383.5%N/A$131.38MN/A0.00N/APLXProtalix BioTherapeutics2.5296 of 5 stars$1.65+6.1%$15.00+811.9%+67.3%$131.16M$61.95M-12.65200Positive News Related Companies and Tools Related Companies Cellectis Alternatives Forte Biosciences Alternatives Inhibikase Therapeutics Alternatives Coherus Oncology Alternatives Alpha Cognition Alternatives Cardiff Oncology Alternatives Zura Bio Alternatives Cabaletta Bio Alternatives TuHURA Biosciences Alternatives Protalix BioTherapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNTI) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredWall Street laughed at Trump’s “Smart Dollar.” Now they’re all in."THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Senti Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Senti Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SNTI Stock Alerts